These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21995462)

  • 1. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
    Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
    Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.
    Chew SC; Lim J; Singh O; Chen X; Tan EH; Lee EJ; Chowbay B
    Eur J Clin Pharmacol; 2014 Feb; 70(2):155-66. PubMed ID: 24193570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
    Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
    Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
    Jada SR; Xiaochen S; Yan LY; Xiaoqiang X; Lal S; Zhou SF; Ooi LL; Chowbay B
    Eur J Clin Pharmacol; 2007 Jun; 63(6):555-63. PubMed ID: 17415554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme differences in SLCO1B3 functional polymorphisms in Roma and Hungarian populations.
    Nagy A; Szalai R; Magyari L; Bene J; Toth K; Melegh B
    Environ Toxicol Pharmacol; 2015 May; 39(3):1246-51. PubMed ID: 26005078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
    Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
    J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
    Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
    Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
    Lee HH; Leake BF; Teft W; Tirona RG; Kim RB; Ho RH
    Mol Cancer Ther; 2015 Apr; 14(4):994-1003. PubMed ID: 25695959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
    Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
    Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
    Sortica Vde A; Ojopi EB; Genro JP; Callegari-Jacques S; Ribeiro-Dos-Santos A; de Moraes MO; Romano-Silva MA; Pena SD; Suarez-Kurtz G; Hutz MH
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):460-8. PubMed ID: 22136368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
    Namgoong S; Cheong HS; Kim JO; Kim LH; Na HS; Koh IS; Chung MW; Shin HD
    Environ Toxicol Pharmacol; 2015 Nov; 40(3):692-7. PubMed ID: 26409184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
    Geng F; Jiao Z; Dao YJ; Qiu XY; Ding JJ; Shi XJ; Li ZD; Zhong MK
    Clin Chim Acta; 2012 Apr; 413(7-8):683-90. PubMed ID: 22227166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).
    Letschert K; Keppler D; König J
    Pharmacogenetics; 2004 Jul; 14(7):441-52. PubMed ID: 15226676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.
    Boivin AA; Cardinal H; Barama A; Pichette V; Hébert MJ; Roger M
    Drug Metab Pharmacokinet; 2010; 25(5):508-15. PubMed ID: 20877131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
    Smith NF; Marsh S; Scott-Horton TJ; Hamada A; Mielke S; Mross K; Figg WD; Verweij J; McLeod HL; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):76-82. PubMed ID: 17186002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
    Xiang X; Jada SR; Li HH; Fan L; Tham LS; Wong CI; Lee SC; Lim R; Zhou QY; Goh BC; Tan EH; Chowbay B
    Pharmacogenet Genomics; 2006 Sep; 16(9):683-91. PubMed ID: 16906022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.